Belgium-based Sequana Medical has released data from the Phase I/II MOJAVE study in the US, which is evaluating its direct sodium removal (DRS) therapy in patients with congestive heart failure.
Following positive data reported earlier this year from a Phase I/II trial, Sequana Medical has touted results from a study showing its device’s superiority in clearing sodium versus traditional ...
Sequana Medical NV received premarket approval from the U.S. FDA for its Alfapump system to treat recurrent or refractory ascites due to liver cirrhosis. Data from the Poseidon pivotal study showed ...
The Price to Earnings (P/E) ratio, a key valuation measure, is calculated by dividing the stock's most recent closing price by the sum of the diluted earnings per share from continuing operations ...
The total number of outstanding shares of the Company mentioned in the relevant transparency notification amounts to 52,416,601, each share giving right to one (1) vote (being 52,416,601 voting rights ...
(1) The total number of outstanding shares of the Company on 24 January 2025 mentioned in the relevant transparency notifications amounts to 52,416,601, each share giving right to one (1) vote (being ...
From February 8 to October 12, 2025, this horsewoman's exceptional costume is on show at the Palais Galliera. The outfit ...
alfapump® is the first US approved active implantable medical device (Class III) for the treatment of recurrent or refractory ascites due to liver cirrhosis US market opportunity estimated at over $2 ...
Conversion of EUR 0.53 million under the Sensinnovat 2020 loan, EUR 1.28 million under the 2024 convertible loan with various shareholders, and EUR 2.68 million under the Kreos 2022 loan into equity, ...